Action Ocean Biomedical - OCEA

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

0,0413

Prix Achat

0,0408

Prix Vente

0,0413

Volume échangé

8 437 338

0,037 Fourchette du Jour 0,042

0,0385 Plage de 52 semaines 2,09

Cap du marché

1,44M

Clôture Veille

0,0432

Ouverture

0,0418

Dernière Transaction

0.0412

Dernière heure de transaction

23:43:57

Volume financier

US$ 341 871

VWAP

0,040519

Volume moyen (3 m)

58 464 696

Actions en circulation

34 868 628

Rendement du Dividende

Ratio Cours sur Bénéfices

-3,03

Bénéfice par action (BPA)

-3,28

Chiffre d'affairess

Bénéfice net

-114,47M

Aesther Healthcare Acquisition Corp is a newly-organized blank check company. It is formed for the purpose effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Aesther Healthcare Acquisition Corp is a newly-organized blank check company. It is formed for the purpose effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.

Secteur

Blank Checks

Industrie

Pharmaceutical Preparations

Site Web

www.aestherhealthcarespac.com

Siège social

Dover, Delaware, USA

Fondé

2021

Ocean Biomedical Inc est coté dans le secteur Blank Checks de la NASDAQ avec le ticker OCEA. Le dernier cours de clôture d'Ocean Biomedical était de US$0,04. Au cours de la dernière année, les actions de Ocean Biomedical ont été négociées dans une fourchette de prix de US$ 0,0385 à US$ 2,09.

Ocean Biomedical compte actuellement 34 868 628 actions en circulation. La capitalisation boursière d'Ocean Biomedical est de US$1,51 million. Ocean Biomedical a un ratio cours/bénéfice (ratio PE) de -3.03.

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a...

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb...

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Providence, RI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that its...

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

PROVIDENCE, Rhode Island, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today...

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

PROVIDENCE, Rhode Island, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today...

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical’s Anti-CHI3L1 patent coverage includes multiple methods of use for targeting a broad range of...

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.0057	-12.1276595745	0.047	0.048	0.04	7078020	0.04420413	CS
4	-0.0176	-29.8811544992	0.0589	0.136	0.0385	67273414	0.07725927	CS
12	-0.4007	-90.6561085973	0.442	0.6594	0.0385	58464696	0.12851254	CS
26	-0.9487	-95.8282828283	0.99	1.1	0.0385	27688185	0.13084654	CS
52	-1.7387	-97.6797752809	1.78	2.09	0.0385	13698742	0.13796689	CS
156	-9.9187	-99.5853413655	9.96	26.5986	0.0385	7655921	0.95086737	CS
260	-9.9187	-99.5853413655	9.96	26.5986	0.0385	7655921	0.95086737	CS

OCEA - Frequently Asked Questions (FAQ)

What is the current Ocean Biomedical share price?

The current share price of Ocean Biomedical is US$ 0,0413

How many Ocean Biomedical shares are in issue?

Ocean Biomedical has 34 868 628 shares in issue

What is the market cap of Ocean Biomedical?

The market capitalisation of Ocean Biomedical is USD 1,51M

What is the 1 year trading range for Ocean Biomedical share price?

Ocean Biomedical has traded in the range of US$ 0,0385 to US$ 2,09 during the past year

What is the PE ratio of Ocean Biomedical?

The price to earnings ratio of Ocean Biomedical is -3,03

What is the reporting currency for Ocean Biomedical?

Ocean Biomedical reports financial results in USD

What is the latest annual profit for Ocean Biomedical?

The latest annual profit of Ocean Biomedical is USD -114,47M

What is the registered address of Ocean Biomedical?

The registered address for Ocean Biomedical is 8 THE GREEN, STE A, KENT, DOVER, DELAWARE, 19901

What is the Ocean Biomedical website address?

The website address for Ocean Biomedical is www.aestherhealthcarespac.com

Which industry sector does Ocean Biomedical operate in?

Ocean Biomedical operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
SHFSSHF Holdings Inc	US$ 3,93 (76,23%)	1,82M
DRCTDirect Digital Holdings Inc	US$ 0,8799 (37,48%)	5,42M
ADDColor Star Technology Company Ltd	US$ 0,970126 (25,26%)	501,29k
XCURExicure Inc	US$ 10,40 (23,22%)	7,11k
FUFUBitFuFu Inc	US$ 5,05 (16,90%)	22,54k
AREBAmerican Rebel Holdings Inc	US$ 3,34 (-35,27%)	637,18k
LXEHLixiang Education Holding Company Ltd	US$ 5,00 (-26,90%)	312,61k
PNBKPatriot National Bancorp Inc	US$ 2,70 (-17,68%)	220,87k
YGMZMingZhu Logistics Holdings Limited	US$ 0,84 (-16,83%)	36,13k
FTELFitell Corporation	US$ 0,5406 (-15,53%)	29,64k
DMNDamon Inc	US$ 0,0035 (2,94%)	29,44M
SUNESUNation Energy Inc	US$ 0,0169 (-15,50%)	13,91M
STSSSharps Technology Inc	US$ 0,03 (-6,25%)	5,83M
DRCTDirect Digital Holdings Inc	US$ 0,8799 (37,48%)	5,42M
SYRASyra Health Corporation	US$ 0,1155 (10,74%)	3,03M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ocean Biomedical Inc (OCEA) Cours

Ocean Biomedical Inc (OCEA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Ocean Biomedical Inc

OCEA Dernières nouvelles

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Form 8-K - Current report

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Form 8-K - Current report

Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China

Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development

Ocean Biomedical Advances Malaria Vaccine Research with New NIH Funding and Expedited Development Pathway

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms

Form 8-K - Current report

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Form 8-K - Current report

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

OCEA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités